by Maria Zannes | Aug 14, 2024 | Press Releases
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales Q2 CyPath® Lung test sales up 217% over Q1 2024 Expanded CyPath® Lung test sales to physicians in California and Ohio; now receiving orders from physicians in eight...
by Maria Zannes | Aug 2, 2024 | Press Releases
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO, TX (August 2, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),...
by Maria Zannes | Jul 9, 2024 | Press Releases
Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO, TX (July 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for...
by Maria Zannes | Jun 12, 2024 | Press Releases
Sales of CyPath® Lung tests, onboarding of pulmonology practices ahead of forecasts SAN ANTONIO, TX (June 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection...
by Maria Zannes | May 15, 2024 | Press Releases
Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original...
by Maria Zannes | May 2, 2024 | Press Releases
SAN ANTONIO, Texas (May 2, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month Sales of CyPath® Lung, our noninvasive diagnostic test for the early detection of lung cancer, continue...
